Enveda announces Series E financing to advance clinical development
Enveda →Enveda announced that it had closed a Series E financing led by Catalio Capital Management, with participation from new and existing investors. The company said it intended to advance its clinical-stage programs, introduce additional candidates into trials and expand its AI-enabled drug discovery platform. George Petrocheilos, Catalio’s co-founder and managing partner, joined Enveda’s board in connection with the financing. The announcement linked the investment to the company’s transition from discovery into later clinical development. It also cautioned that its candidates remained investigational, that anticipated trial milestones were forward-looking and that early clinical findings might not predict outcomes in later studies.